The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott ...

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Edwards Lifesciences Corp (EW) reports a robust 12.7% sales growth in Q1 2026, raises full-year guidance, and showcases significant advancements in TAVR and TMTT segments.

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter aortic valve replacement (TAVR), the investigational Emboliner device ...

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from aortic regurgitation, a potentially dangerous condition that occurs ...

The FDA has granted pre-market approval to JenaValve’s Trilogy system, the first transcatheter aortic valve replacement (TAVR) device in the U.S. specifically indicated for severe aortic regurgitation ...

On August 6, the Federal Trade Commission (FTC) challenged Edwards Lifesciences Corp.'s proposed $945 million acquisition of JenaValve Technology, Inc. The deal would combine the two leading companies ...

Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or severe ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...